1 |
ISU ABXIS has signed a license agreement for “Fabagal” a therapeutic for Fabry disease, with NPO Petrovax Pharm located in Russia
|
2022-01-26 |
379 |
2 |
ISU ABXIS to Present at Neuroscience 2021
|
2021-10-05 |
112 |
3 |
ISU ABXIS to Present Positive Phase 1 Data set on ISU104 Monotherapy or in Combination with Cetuximab in Patients with R/M HNSCC at ESMO Congress 2021
|
2021-10-01 |
96 |
4 |
ISU ABXIS Announced Presentations at ESMO Congress 2021
|
2021-09-29 |
53 |
5 |
ISU ABXIS Announces Formation of Its Global Scientific Advisory Board
|
2021-07-09 |
79 |
6 |
ISU ABXIS Received European Patent Protection for ‘ISU104’
|
2021-07-05 |
64 |
7 |
ISU ABXIS Presents at ESMO Virtual Congress 2020
|
2020-09-16 |
42 |
8 |
ISU ABXIS Announced Completion of Phase 1 Study for ISU305
|
2020-08-20 |
34 |
9 |
ISU ABXIS Presentations at 2020 AACR Virtual Annual Meeting II
|
2020-05-20 |
22 |
10 |
ISU ABXIS to Participate the JP Morgan Healthcare Conference 2020
|
2020-01-06 |
22 |